Literature DB >> 27288300

Polymorphisms of HLA-DQB1 predict survival of hepatitis B virus-related hepatocellular carcinoma patients receiving hepatic resection.

Xiaoguang Liu1, Long Yu1, Chuangye Han1, Sichong Lu1, Guangzhi Zhu1, Hao Su1, Wei Qin1, Xiwen Liao1, Tao Peng2.   

Abstract

OBJECTIVE: Human leukocyte antigen (HLA)-DQB1 genetic polymorphisms are associated with an increased risk of hepatitis B virus-related hepatocellular carcinoma (HBV-related HCC). We aimed to evaluate the influence of genetic polymorphisms in HLA-DQB1 exon region and neighboring single nucleotide polymorphisms (SNPs rs9275572 and rs2244546) on survival of HBV-related HCC patients undergoing hepatic resection.
METHODOLOGY: All SNPs were genotyped by sequencing DNA isolated from tumor samples of 483 patients with HBV-related HCC.
RESULTS: We identified rs9275572 and HLA-DQB1 haplotype CCCCC (constituted by rs1130375C, rs12722107C, rs12722106C, rs36222416C and rs3189152C) were significantly associated with overall survival (OS) of HBV-related HCC patients (P=0.015 and 0.049, respectively), after adjusting for serum AFP level, the Barcelona Clinic Liver Cancer (BCLC) stages, Child-Pugh score, regional invasion, radical hepatic resection and adjuvant antiviral treatment. In stratified analyses, the AG/GG genotype of rs9275572 significantly decreased risk of death among patients with younger age, serum AFP levels ≥400ng/mL, tumor size ≥10cm, BCLC stage A and radical hepatic resection. HLA-DQB1 haplotype CCCCC was significantly protective for male patients, patients with serum AFP levels <400ng/mL, tumor size ≥10cm, BCLC stage B/C, postoperative adjuvant TACE/TAC/TAE, radical hepatic resection and patients with adjuvant antiviral treatment. Moreover, gene-dosage effects were also observed, patients with SNP rs9275572 AG/GG genotypes and Block2 CCCCC haplotype had a decreased risk of death compared to others after adjusting for serum AFP level, BCLC stages, Child-Pugh score, regional invasion, radical hepatic resection and adjuvant antiviral treatment (adjusted HR=0.38, 95% CI=0.20-0.73, P=0.004).
CONCLUSIONS: The AG/GG genotype of rs9275572 and HLA-DQB1 Block2 CCCCC haplotype may have protective effects in HBV-related HCC patients receiving hepatic resection. Copyright Â
© 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27288300     DOI: 10.1016/j.clinre.2016.04.005

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


  4 in total

1.  Dynamic edge-based biomarker non-invasively predicts hepatocellular carcinoma with hepatitis B virus infection for individual patients based on blood testing.

Authors:  Yiyu Lu; Zhaoyuan Fang; Meiyi Li; Qian Chen; Tao Zeng; Lina Lu; Qilong Chen; Hui Zhang; Qianmei Zhou; Yan Sun; Xuefeng Xue; Yiyang Hu; Luonan Chen; Shibing Su
Journal:  J Mol Cell Biol       Date:  2019-08-19       Impact factor: 6.216

2.  HLA-DQB1-AS1 Promotes Cell Proliferation, Inhibits Apoptosis, and Binds with ZRANB2 Protein in Hepatocellular Carcinoma.

Authors:  Jianwu Long; Longfei Liu; Xiaoyun Zhou; Xianzhou Lu; Lei Qin
Journal:  J Oncol       Date:  2022-05-11       Impact factor: 4.501

3.  Comprehensive investigation of cytokine- and immune-related gene variants in HBV-associated hepatocellular carcinoma patients.

Authors:  Fengxue Yu; Xiaolin Zhang; Suzhai Tian; Lianxia Geng; Weili Xu; Ning Ma; Mingbang Wang; Yuan Jia; Xuechen Liu; Junji Ma; Yuan Quan; Chaojun Zhang; Lina Guo; Wenting An; Dianwu Liu
Journal:  Biosci Rep       Date:  2017-12-12       Impact factor: 3.840

4.  Genome-wide association pathway analysis to identify candidate single nucleotide polymorphisms and molecular pathways associated with TP53 expression status in HBV-related hepatocellular carcinoma.

Authors:  Xiwen Liao; Long Yu; Xiaoguang Liu; Chuangye Han; Tingdong Yu; Wei Qin; Chengkun Yang; Guangzhi Zhu; Hao Su; Tao Peng
Journal:  Cancer Manag Res       Date:  2018-05-01       Impact factor: 3.989

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.